

Creating New Valuable Working Model Through Strategic Partnership With Clients 以战略合作伙伴为导向,创造价值服务的新模式

Sally Sha BD Director of Tigermed


May.17,2012

www.tigermed.net



TIGERMED CONSULTING CO., LTD






China growth as one of the largest pharma

Top 13 pharmaceuticals market 2010 (USDbn)


Top 13 pharmaceuticals markets 2015F (USDbn)



China Pharmaceutical market size(USDm)rmed

TIGERMED CONSULTING CO., LTD

China pharmaceutical market size (USDm)




Source: BMI, IMS, broker research

R&D driven companies dominated clinical trials Tigermed


TIGERMED CONSULTING CO., LTD

Healthcare companies with pipeline compounds by country of headquarter



Source: MedTrack Pipeline Database, August 2011

The Trend of Partnering Models of Outsourcing



Tigermed


Service provided for clients in the Development of New Drug







China's Innovation favorite for New Modelsned



Big Pharma Unmet Needs




- Clinical stage products
- ✓ Preclinical candidates
- ✓ Platforms
- ✓ Unique expertise
- ✓ Therapeutic area alignment
- ✓ Biomarkers
- ✓ Compelling biology
- ✓ IP / Novelty
- ✓ Risk mitigation
- ✓ Access to emerging markets

How to Create New Value



TIGERMED CONSULTING CO., LTD

-Rich experience -Strong team -Acquaint with Sponsor's needs



-Capability -Infrastructure -Communication -Knowledge & patient pool

Successful case--Tigermed



大连 青岛の Shiyan Offic 嘉兴 Wenzhou Office Kunming Office ... 南宁 Nanning Office 广州 深圳 Guangzhou Offic **香港** ongkong Office 海口 **Haikou Office**

 Board Geographic Coverage: Up to Mar. 2012, Tigermed operates 7 subsidiaries, 40offices in China mainland and China Hongkong.

- Strong Capability: Specialized in providing Phase I-IV clinical trials, data management, biostatistics and regulatory services to healthcare products
- Dedicated Team: 620 employees in total

What are the value of CRO



TIGERMED CONSULTING CO., LTD




Solution packages instead of sole service




Tigermed-Powering the Healthcare Product Development in China

Tigermed




KSF for strategic partnerships





Experience in Global Trials

TIGERMED CONSULTING CO., LTD



More than 65 MCT with 30 more clients in the several key therapeutic areas

Tigermed-Powering the Healthcare Product Development in China


Data updated till Mar. 2012

Tigermed

Rich Experience in Innovative Drugs

TIGERMED CONSULTING CO., LTD

- Through our unmatched experience and outstanding achievements in the development of 36 innovative drugs (26 NCEs and 10 new biological products), 75studies, Tigermed is recognized as "An Innovative CRO" in China.
- Therapeutic areas include: HBV, oncology, endocrine, cardiovascular, AIDS and etc.
 21



New Chemical Entity New Biologics

Tigermed-Powering the Healthcare Product Development in China

Data updated till Mar. 2012

Key Challenges CROs Faced



- Higher professional standard and demanding request from clients
- Deliver effective but well Rol results for MCT
- Leadership in the industry and good rapport with sites/PI/investigators/authorities
- A stable but workable task forth
- Edging cutting knowledge
- Dynamic / fluid Environment
- Conflicts solving
- Ethical concerns



Key leanings of cooperation



- Self-awareness of both parties
- Aligned strategic objectives
- Manage expectations around company culture differences
- Develop key relationships
- Close project management
 - Sensitivity to timelines, budget, reporting and deliverables
- Effective communication
 - Language, time zones, regional culture
 - Metrics risk management

